Related Experiment Video
Updated: Feb 22, 2026
12:04
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
29.6K
Randomized Controlled Trials in Neuroendocrine Tumors.
John C McAuliffe1, Edward M Wolin2
1Department of Surgery, Montefiore-Einstein Center for Cancer Care, 1521 Jarrett Place, Suite 207, Bronx, NY 10461, USA.
Surgical Oncology Clinics of North America
|September 20, 2017
Summary
Neuroendocrine tumor understanding has grown, increasing diagnosis due to advanced imaging and screening. This review covers key trials for these diverse malignancies.
Area of Science:
- Oncology
- Endocrinology
Background:
- Neuroendocrine tumor (NET) knowledge has significantly advanced in the past 20 years.
- Increased use of cross-sectional imaging and endoscopic screening contributes to a higher prevalence of diagnosed NETs.
- NETs are a heterogeneous group of cancers with variable clinical behaviors, and up to 35% of patients present with symptoms.
Purpose of the Study:
- To critically review major randomized controlled trials (RCTs) in the field of neuroendocrine tumors.
- To provide an overview of ongoing and upcoming clinical trials for NETs.
Main Methods:
- Literature review focusing on pivotal randomized controlled trials for neuroendocrine tumors.
- Identification and summary of key studies evaluating NET management and treatment.
Main Results:
- The review synthesizes findings from significant RCTs, highlighting advancements in understanding and managing NETs.
- Several important clinical trials for neuroendocrine tumors are currently in progress or nearing completion.
Conclusions:
- The field of neuroendocrine tumors has seen substantial progress, driven by research and improved diagnostic capabilities.
- This review offers a critical perspective on the evidence base from RCTs and future research directions in NETs.
